|
EDX Medical Group PLC on Monday shared plans to move its listing to London’s AIM from the Aquis Exchange, alongside expectations of ‘record’ revenue in financial 2026. The Cambridge, England-based developer of digital diagnostic products and services has applied under a ‘streamlined admission process’ called the ‘AIM Designated Market’ route intended for companies previously traded on Aquis. It listed on the Access segment of the Aquis Growth Market back in 2021, but was renamed EDX Medical in 2022 as part of a reverse takeover by EDX Medical Ltd. It then moved to Apex segment in 2024, and because it has been listed there for more than 18 months, it is not required to publish an admission document before joining AIM. EDX Medical explained that it was making the move to support future fundraising. ‘The company will continue to require capital to fulfil its potential and believe that its access to capital from certain funds, its liquidity profile and visibility to investors will be improved by the AIM admission,’ it said. Since 2022, EDX Medical has reported having raised £15.5 million, alongside securing distribution deals and hiring more staff. For the year ended March 31, the company expects to post ‘record’ revenue of about £1.2 million, compared to £122,608 the year prior, when sales had declined from £227,986 in financial 2024. The improvement ‘has been driven by the recent focus on the distribution of prostate cancer tests which has compensated for some delay to the regulatory approvals for some of the EDC tests and slower sales of some of the more complex tests,’ EDX Medical said. It ended March with around £2.9 million in cash, compared with around £2.4 million on-year. ‘In order to mitigate the downside risk of revenue expectations not being achieved or equity not being available on appropriate terms the Company has entered into a working capital facility from Sir Christopher Evans,’ EDX Medical noted. This is for up to £3.71 million, and is in addition to an existing loan from Evans of £2.0 million. As of Monday, Evans is the company’s largest shareholder with a stake of about 33%. EDX Medical previously had described financial 2025 as a ‘transitional year’, noting ahead of its proposed admission to AIM that is ‘unlikely to be in a position to pay dividends in the short to medium term’. The company’s shares were last quoted at 10.75 pence each on Aquis. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
